SCHEMBL4879933

SCHEMBL4879933

Cc1nc2c(Br)cc(Br)cn2c1C

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRNP P04156 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HTT P42858 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
NOD2 Q9HC29 1/20 0.33
RXFP1 Q9HBX9 2/20 0.33
TSHR P16473 1/20 0.32
GAA P10253 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
ATP4A P20648 2/20 0.31
ATP4B P51164 2/20 0.31
CYP3A4 P08684 6/20 0.31
CYP2C9 P11712 6/20 0.31
CYP2D6 P10635 3/20 0.30
CYP2C19 P33261 3/20 0.30
CYP1A2 P05177 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4575125 0.81 APP (0.34) HTTL3MBTL1LMNAHPGDRXFP1
SCHEMBL25103350 0.81 NMT1 (0.33) PRNPHTTL3MBTL1RXFP1GAA
SCHEMBL31211004 0.79 AKT1 (0.40) PRNPNPSR1RXFP1GAAALDH1A1
SCHEMBL16268761 0.72 MEN1 (0.36) L3MBTL1LMNARXFP1MAPT
SCHEMBL4888747 0.72 CYP2C9 (0.47) CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2
SCHEMBL4887393 0.72 CYP2C9 (0.56) ALDH1A1CYP3A4CYP2C9CYP2D6CYP2C19
SCHEMBL25974150 0.72 KMT2A (0.39) NPSR1HTTHPGDTSHRGAA
SCHEMBL10921260 0.71 ATP4A (0.53) ALDH1A1MAPTATP4AATP4BCYP3A4
SCHEMBL4890938 0.70 CYP3A4 (0.61) ATP4AATP4BCYP3A4CYP2C9CYP2D6
SCHEMBL5212872 0.69 ATP4A (0.52) HTTL3MBTL1ALDH1A1MAPTATP4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311740-A1 IMIDAZOPYRIDINE DERIVATIVES AS ACID PUMP ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-12-09 US disclosed
US-20100311740-A1 IMIDAZOPYRIDINE DERIVATIVES AS ACID PUMP ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-12-09 US disclosed
US-20080255358-A1 Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases GLAXO GROUP LIMITED (GB) 2008-10-16 US disclosed
US-20080255358-A1 Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases GLAXO GROUP LIMITED (GB) 2008-10-16 US disclosed
US-20080255358-A1 Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases GLAXO GROUP LIMITED (GB) 2008-10-16 US disclosed
WO-2007003386-A9 IMIDAZOPYRIDINE DERIVATIVES AS ACID PUMP ANTAGONISTS GLAXO GROUP LTD (GB) 2008-09-18 WO disclosed
US-7223771-B2 Tricyclic imidazopyridines ALTANA PHARMA AG (DE) 2007-05-29 US disclosed
US-7223771-B2 Tricyclic imidazopyridines ALTANA PHARMA AG (DE) 2007-05-29 US disclosed
US-7223771-B2 Tricyclic imidazopyridines ALTANA PHARMA AG (DE) 2007-05-29 US disclosed
US-7189736-B2 Prodrugs of imidazopyridine derivatives ALTANA PHARMA AG (DE) 2007-03-13 US disclosed
EP-1313739-A1 ALKYLATED IMIDAZOPYRIDINE DERIVATIVES ALTANA Pharma AG (DE) 2003-05-28 EP disclosed
EP-1303519-A1 TRICYCLIC IMIDAZOPYRIDINES ALTANA Pharma AG (DE) 2003-04-23 EP disclosed
WO-2001072748-A9 IMIDAZOPYRIDIN-8-ONES ALTANA PHARMA AG (DE) 2003-04-10 WO disclosed
EP-1286993-A1 IMIDAZOPYRIDIN-8-ONES ALTANA Pharma AG (DE) 2003-03-05 EP disclosed
WO-2003014123-A1 TRICYCLIC IMIDAZOPYRIDINES ALTANA PHARMA AG (DE) 2003-02-20 WO disclosed
WO-2002034749-A1 POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2002-05-02 WO disclosed
WO-2001072757-A1 TRICYCLIC IMIDAZOPYRIDINES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072748-A1 IMIDAZOPYRIDIN-8-ONES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072754-A1 ALKYLATED IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072756-A1 PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255358-A1 Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases ALPI, PYGL, PPIP5K2 PRNP 1023/4885NPSR1 2158/4885HTT 4293/4885
US-20100311740-A1 IMIDAZOPYRIDINE DERIVATIVES AS ACID PUMP ANTAGONISTS HRH2, GIPR, MLNR PRNP 3637/4885NPSR1 1013/4885HTT 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.